Adagene

Adagene P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Adagene (ADAG) as of Nov 4, 2026 is -15.06. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -7.94 — a change of 89.69% (lower).

P/CF

-15.06

YoY

89.69%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Adagene is 2025 -15.06 . P/CF (Price-to-Cash-Flow Ratio) of Adagene was 2024 -7.94 . It decreases by 89.69% lower compared to the previous year.

The Adagene P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-16.54 USD
Jan 1, 2019
-12.99 USD
Jan 1, 2020
-8.27 USD
Jan 1, 2021
-5.43 USD
Jan 1, 2022
-4.85 USD
Jan 1, 2023
-8.29 USD
Jan 1, 2024
-7.94 USD
Jan 1, 2025
-15.06 USD
The Adagene P/CF history
YEARP/CFYoY
-15.06+89.69%
-7.94-4.20%
-8.29+70.84%
-4.85-10.69%
-5.43-34.29%
-8.27-36.37%
-12.99-21.42%
-16.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adagene Stock analysis

What does Adagene do? Adagene Inc. develops monoclonal antibody drugs for cancer treatment in China, focusing on clinical-stage products. Its lead candidate ADG126, a masked anti-CTLA-4 mAb, is in phase 1b/2 trials for cancer. The company also advances ADG116, a fully human anti-CTLA-4 antibody using NEObody technology, in phase 1b/2 for solid tumors. ADG206 targets advanced metastatic solid tumors in phase 1, while ADG104, an anti-PD-L1 antibody, is in phase 2 development. Additional candidates include ADG125 for phase 2 studies, ADG138 for low-expressing tumors, and ADG152 for off-tumor toxicities, all in preclinical stages. The company's pipeline targets various cancer types through innovative antibody technologies. Adagene generates revenue through the development and commercialization of its antibody drug candidates. It focuses on clinical trials for products like ADG126, ADG116, and ADG104, aiming to secure partnerships with pharmaceutical companies for later-stage development and marketing. The company's products target advanced cancer treatments, appealing to oncology-focused pharmaceutical firms seeking novel therapies. ADG153, a masked anti-CD47 antibody, and CD28 T-cell engagers represent further pipeline opportunities for collaboration in oncology drug development. Adagene's business model centers on advancing its pipeline through clinical trials to attract potential partners. The company's focus on anti-CTLA-4, anti-PD-L1, and novel antibody technologies positions it for strategic collaborations. Its products target unmet needs in cancer treatment, particularly for resistant or metastatic tumors. The company's preclinical and clinical-stage candidates, including ADG138 and ADG152, are designed to address specific oncology challenges, making them attractive for pharmaceutical partnerships. Adagene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adagene stock

P/CF (Price-to-Cash-Flow Ratio) of Adagene is -15.06 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Adagene changed from -7.94 to -15.06, representing a 89.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Adagene since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Adagene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Adagene

All Key Metrics — Adagene